Seleção de populações de Lotus corniculatus L. com maior tolerância ao alumínio em solução nutritiva Selection of populations of Lotus corniculatus L. with increased tolerance to aluminum in nutrient solution

O experimento foi realizado com o objetivo de selecionar genótipos de Lotus corniculatus L. (Draco, São Gabriel e UFRGS) mais tolerantes ao alumínio, utilizando-se a técnica de seleção em solução nutritiva. A solução continha 200 µmol/L de cálcio (CaCl2), 100 µmol/L de alumínio (AlCl3) e pH controlado na faixa de 4,1 a 4,3. Realizaram-se dois ciclos de seleção, nos quais as plântulas foram selecionadas pelo comprimento final das radículas. Posteriormente, avaliou-se o ganho genético alcançado nos ciclos de seleção, tanto nas populações originais como nas melhoradas, em um experimento com solução nutritiva com quatro concentrações de alumínio (0, 50, 100 e 150 µmol/L) (AlCl3), por meio do crescimento radicular líquido. O uso de solução nutritiva foi eficiente na seleção de plântulas de cornichão tolerantes ao alumínio. Os materiais analisados apresentam diferenças em relação a esta característica, destacando-se o genótipo UFRGS F2, proveniente de dois ciclos de seleção, como o material com maior tolerância ao alumínio.<br>The experiment was carried out to select genotypes of Lotus corniculatus L. (Draco, São Gabriel and UFRGS) more tolerant to aluminum, using the technique of selection in nutrient solution. The solution contained 200 µmol/L calcium (CaCl2) and 100 µmol/L aluminum (AlCl3) and a pH controlled in the range from 4.1 to 4.3. It was performed two cycles of selection, in which the seedlings were selected by the root final length. Subsequently, the genetic gain achieved in the cycles of selection was tested, in original and improved populations in an experiment in nutrient solution with four concentrations of aluminum (0, 50, 100 and 150 µmol/L) (AlCl3), by liquid root growth. Use of nutritional solution was efficient in the selection of seedlings of birdsfoot trefoil tolerant to aluminum. The materials analyzed differ for this characteristic, with the genotype UFRGS F2, being the most tolerant

Lowered Cisplatin Dose And No Bleomycin In The Treatment Of Pediatric Germ Cell Tumors: Results Of The Gct-99 Protocol From The Brazilian Germ Cell Pediatric Oncology Cooperative Group

Purpose We describe the results of a risk-adapted, response-based therapeutic approach from the Brazilian GCT-99 study on germ cell tumors. Patients and Methods From May 1999 to October 2009, 579 participants were enrolled in the Brazilian GCT-99 study. Treatment, defined as specific chemotherapy regimen and number of cycles, was allocated by means of risk-group assignment at diagnosis with consideration for stage and primary tumor site. Patients at low risk received no chemotherapy. Patients at intermediate risk (IR) with a good response (GR) received four cycles of platinum and etoposide (PE), for total doses of platinum 420 mg/m2 and etoposide 2,040 mg/m2. Patients at IR with a partial response (PR) received three cycles of PE plus three cycles of ifosfamide, vinblastine, and bleomycin. Patients at high risk (HR) with a GR received four cycles of PE and ifosfamide (PEI) at total doses of platinum 420 mg/m2, etoposide 1,200 mg/m2, and ifosfamide 30 g/m2. Patients at HR with a PR received six cycles of PEI. Results The risk-group distribution was 213 LR, 138 IR, and 129 HR for 480 evaluable patients. Overall survival (OS) and event-free survival (EFS) rates at 10 years were, respectively, 90% and 88.6% in the IR-GR group (n = 126) and 74.1% and 74.1% in the IR-PR group (n = 12). Ten-year rates for the HR-GR group (n = 86) were an OS of 66.8% and an EFS of 62.5%. The HR-PR group (n = 43) had an OS of 74.8% and an EFS of 73.4%. In univariable and multivariable analysis, increased serum lactate dehydrogenase level and histology for a metastatic immature teratoma were prognostic of a worsened outcome. Conclusion Reduction of therapy to two drugs did not compromise survival outcomes for patients in the IR-GR group, and escalation of therapy with PEI did not significantly improve OS and EFS in patients at HR. © 2016 by American Society of Clinical Oncology.34660361